Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and MeSH Terms (11)
Adult Drug Administration Schedule Drug Resistance, Viral Female HIV-1 HIV Infections Humans Male Mutation Reverse Transcriptase Inhibitors Viral Load
This publication is referenced by other Labnodes entities: